Taniuchi S, Higashino H, Takaya J, Ishizaki Y, Kino M, Man W, Kobayashi Y
Department of Pediatrics, Kansai Medical University.
Jpn J Antibiot. 1994 Nov;47(11):1553-8.
Cefozopran (CZOP, SCE-2787), a new parenteral cephem, was evaluated for its antibacterial activity and clinical efficacy. CZOP, 24.0-78.0 mg/kg/day, was given to 11 pediatric patients in 3 dose a day via 30-minute drip infusion. Clinically evaluated were nine patients including 4 with acute pneumonia, 2 with urinary tract infections, 2 with lymphadenitis and 1 with sepsis. Two patients were excluded because of possible non-bacterial infections. Clinical efficacies were excellent in 5, good in 3 and fair in 1. Bacteriological responses were confirmed for 5 strains in 5 patients. Four strains were eradicated, but one strain was not. MICs of CZOP were equal to those of ceftazidime. Side effects or abnormal laboratory test results were observed in 3 patients; diarrhea in 1, elevated GPT in 1 and thrombocytosis in 1, but none of them was significant.
头孢唑兰（CZOP，SCE - 2787）是一种新型胃肠外头孢菌素，对其抗菌活性和临床疗效进行了评估。对11名儿科患者以24.0 - 78.0mg/kg/天的剂量，分3次给药，通过30分钟静脉滴注。临床评估的9名患者中，包括4例急性肺炎、2例尿路感染、2例淋巴结炎和1例败血症患者。2例患者因可能的非细菌感染被排除。临床疗效为优5例、良3例、中1例。5例患者中的5株菌株得到细菌学反应确认。4株菌株被根除，但1株未被根除。头孢唑兰的最低抑菌浓度与头孢他啶相当。3例患者观察到副作用或实验室检查结果异常；1例腹泻、1例谷丙转氨酶升高、1例血小板增多，但均不显著。
